Mitral re-valve-in-valve as a new perspective for high-risk patients with prosthetic valve dysfunction: case reports

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
Citação
EUROPEAN HEART JOURNAL-CASE REPORTS, v.7, n.12, article ID ytad579, 6p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Mitral valve diseases are a common medical condition, and surgery is the most used therapeutic approach. The need for less invasive interventions led to the development of transcatheter valve implantation in high-risk patients. However, the treatment to the dysfunctions of these prosthetic valves is still uncertain, and the yield and safety of repeated transcatheter valve implantations remain unclear.Cases summary A 69-year-old Caucasian woman with three previous mitral valve procedures performed due to rheumatic valve disease (currently with a biological prosthetic mitral valve) and a 76-year-old Latin woman with previous liver transplantation (due to metabolic-associated fatty liver disease) and biological mitral prosthesis due to mitral valve prolapse with severe regurgitation underwent mitral valve-in-valve (ViV) transcatheter implantation at the time of dysfunction of their surgical prostheses. Later, these patients developed prosthetic valve dysfunction and clinical worsening, requiring another invasive procedure. Due to maintained high-risk status and unfavourable clinical conditions for surgery, re-valve-in-valve (re-ViV) was performed.Discussion Valve-in-valve transcatheter mitral valve implantation was approved in 2017, and, since then, it has been used in several countries, mainly in high-risk patients. Nevertheless, these prosthetic valves may complicate with stenosis or regurgitation, demanding reinterventions. Although there are favourable data for mitral ViV, re-ViV still lacks robust data to support its performance, with only case reports in the literature so far. It is possible that in high-risk patients, there is a greater benefit from re-ViV when compared with the surgical strategy. However, this hypothesis must be studied in future controlled trials.
Palavras-chave
Mitral valve prosthesis, Transcatheter valve implantation, Prosthesis failure, Case reports
URI
https://observatorio.fm.usp.br/handle/OPI/58334
Referências
  1. de Siqueira DAA, 2020, ARQ BRAS CARDIOL, V115, P525, DOI 10.36660/abc.20200575
  2. Enta Y, 2021, J CARDIOL, V77, P555, DOI [10.1016/j.jjcc.2020.10.0200914-5087/, 10.1016/j.jjcc.2020.10.020]
  3. Graf C, 2008, AM J NURS, V108, P52, DOI 10.1097/01.NAJ.0000314810.46029.74
  4. Ismayl M, 2023, AM J CARDIOL, V189, P98, DOI 10.1016/j.amjcard.2022.11.043
  5. Khan MH, 2023, AM J CASE REP, V24, DOI 10.12659/AJCR.938415
  6. Mack M, 2021, J AM COLL CARDIOL, V78, P2326, DOI 10.1016/j.jacc.2021.07.058
  7. Onorati F, 2018, J CARDIOTHOR VASC AN, V32, P646, DOI 10.1053/j.jvca.2017.09.039
  8. Urena M, 2021, CIRCULATION, V143, P178, DOI 10.1161/CIRCULATIONAHA.120.048147
  9. Vahanian A, 2022, EUR HEART J, V43, P2022, DOI 10.1093/eurheartj/ehac051
  10. Wallace Meredith, 2007, Urol Nurs, V27, P93
  11. Ye J, 2015, JACC-CARDIOVASC INTE, V8, P1735, DOI 10.1016/j.jcin.2015.08.012
  12. Yoon SH, 2019, EUR HEART J, V40, P441, DOI 10.1093/eurheartj/ehy590
  13. Yoon SH, 2017, J AM COLL CARDIOL, V70, P1121, DOI 10.1016/j.jacc.2017.07.714

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - LIM/64